ArticleInternational journal of cancer2025
Germline variants observed in pediatric cancer patients related to hereditary breast and ovarian cancer in adults.
Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Germline variants observed in pediatric cancer patients related to hereditary breast and ovarian cancer in adults.International journal of cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Genetic predisposition is a major cause of cancer, yet little is known about the role of adult cancer predisposition syndromes (CPSs) in childhood cancers. Although extensively studied in adults, information about the impact of germline variants in genes associated with hereditary breast and ovarian cancer (HBOC) remains scarce in the pediatric context. To elucidate whether (likely) pathogenic variants (LP/PVs) in 25 selected HBOC-related genes may contribute to cancer risk in children, we analyzed the spectrum of occurring germline variants. We assessed 372 children (median age at diagnosis 5.1 [0-22.2] years; 160 girls [43%]), including 212 (57%) with hematologic neoplasms, 71 (19%) with brain tumors, and 89 (24%) with various solid entities. Twenty-seven of 372 patients (7%) carried LP/PVs in the candidate genes; for 12 of 27 (44%) no CPS was suspected prior to genotyping. LP/PV carriers were particularly at risk for second malignancies (SMN; 5/27 vs. 13/345; OR = 5.8; p = .0021); yet, LP/PVs in SMN-developing patients resided exclusively in TP53 (n = 3), NBN (n = 1), and ATM (n = 1). Burden testing of our single-center cohort revealed considerable associations between monoallelic LP/PVs in five HBOC-related genes (TP53, CHEK2, ATM, NF1, and NBN) and pediatric cancers compared to healthy adults (gnomAD v.3.1.1, non-cancer dataset). Joint analyses adding 1120 individuals from a previous study Zhang et al. (2015) confirmed significant associations for TP53, CHEK2, NF1, and MSH2. Monoallelic LP/PVs in constrained HBOC-related genes are significantly associated with pediatric cancers. However, particularly in clinically unexpected cases, detection of contributing LP/PVs by genotype-driven approaches may improve patient outcomes by enabling risk-adapted therapy and surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.